We are joined by Arlene Sietker-Radtke (The University of Texas MD Anderson Cancer Center) at ESMO 2019 to discuss her presentation on the results from the KEYNOTE-866 trial (NCT03924856). This phase III study investigates perioperative pembrolizumab or placebo in combination with neoadjuvant chemotherapy in cisplatin-eligible patients with muscle-invasive bladder cancer.
Questions
What are the limitations of the current treatment of muscle-invasive bladder cancer with neoadjuvant chemotherapy? (0:04)
What is the rationale for using pembrolizumab in the perioperative treatment setting? (0:37)
Could you tell us about the aims and design of the KEYNOTE-866 study? (1:23)
What are the eligibility criteria for this study? (1:58)
What are the most promising emerging biomarkers for response to pembrolizumab in bladder cancer? (2:28)
Filmed at the European Society for Medical Oncology (ESMO) Congress 2019, Barcelona, Spain.
Speaker disclosure: Arlene Siefker-Radtke has participated in advisory boards for Merck.
touchONCOLOGY.com is an independent information resource supporting physicians, clinicians and leading industry professionals in continuously developing their knowledge, effectiveness and productivity, via free-to-access content in multimedia formats.
